Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Sildenafil Purchase
Popular Articles
Cellulite Cream

Spiration Presents Results Of Two Analyses Of Methods For Evaluating Effectiveness Of Bronchial Valve Treatment For Severe Emphysema
Spiration, Inc., a developer of novel medical devices designed to benefit patients with severe and chronic conditions of the lung, presented results of two analyses of methods used for evaluating U.S. Pilot Study effectiveness of bronchial valve treatment for severe emphysema at the annual American Thoracic Society (ATS) International conference taking place in San Diego May 15 to 22, 2009.
generic viagra online
Family Doctors: An Endangered Breed
"As more medical students shun primary care for higher-paid specialties, experts warn of a severe imbalance that could cripple the nation"s health care system," CNN Money reports. Luis Manriquez, a first-year student at the University of Washington School of Medicine wants to become a family doctor, an increasingly rare ambition. He will "probably make one-fourth the salary of a specialist while trying to pay down $140,000 on average in medical school debt." Manriquez says that "primary care physicians are considered to not do as much as specialists. ò€¦ People have told me that generalists are less respected as doctors."
News of the day
Putting The Patient In Control Next Stage In Personal Healthcare Budgets Announced, UK
Patients are a step closer to getting more say over their healthcare services as plans for a national pilot project reach the next stage, the Department of Health announced.
Oncology

Diamyd(R) Phase III Study Approved For Younger Patients In The US

Diamyd Medical reported that the company has received approval from the US Food and Drug Administration (FDA) to include children with type 1 diabetes from 10 years of age in the company"s Phase III study with the diabetes vaccine Diamyd(R). Diamyd Medical is conducting two parallel phase III studies, one in Europe and one in the USA, comprising a total of 640 patients. The objective of the studies is to evaluate the ability of the Diamyd(R) vaccine to halt or delay the autoimmune attack on the body"s insulin-producing cells, thereby preserving the body"s own ability to produce insulin in children and adolescents with recent-onset type 1 diabetes. The European study, which is being conducted in nine countries, is approved for patients between 10 and 20 years of age, whilst the US study so far has been approved only for patients 16 to 20 years, an age group with few recent-onset type 1 diabetes patients. The company is, with the new approval, allowed to begin enrollment of children from 10 years of age in the US phase III study. "This is a big step forward giving us the opportunity to accelerate patient recruitment in the US," says Elisabeth Lindner, President and CEO of Diamyd Medical. "We are pleased that the approval comes now in connection with the world"s largest diabetes conference, the ADA"s 69th Scientific Sessions, which is currently ongoing in New Orleans." The company will now, in pace with Institutional Review Board (IRB) approvals in USA, increase the number of American pediatric clinics in the study. The application for market approval is, as before, planned for spring 2011. Diamyd Medical is represented at booth #2431 at the ADA"s 69th Scientific Sessions in New Orleans, USA. About Diamyd Medical Diamyd Medical is a Swedish biopharmaceutical company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. The company"s most advanced project is the GAD-based drug Diamyd(R) for type 1 diabetes. Phase III trials for this drug are in progress in both Europe and the US. In addition, the company has started clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson"s disease. The company has currently three clinical-phase products. Diamyd Medical has offices in Sweden and in the US. Shares are listed on the Nasdaq OMX Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements Diamyd Medical AB (publ)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009